

## RESPONSE TO THE PEER REVIEWER COMMENTS

### Reviewer # 1

#### Comment

Nasa and colleagues provide a nice, concise mini-review concerning euglycemic diabetic ketoacidosis, which represents an easily missed diagnosis in the Emergency Department. Regarding euDKA in the context of SGLT-2 inhibitor treatment, please add the following reference, suggesting a class effect, with molecule specific analysis: Douros A, Lix LM, Fralick M, et al. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study. *Ann Intern Med.* 2020;173(6):417-425. doi:10.7326/M20-0289

Response: We thank the reviewer for a prompt review and kind comments.

The reference regarding the class effect of SGLT2 inhibitors on euglycemic DKA has been added (Page 6, paragraph 2, Line 4).

#### Comment:

Please also discuss on the results of a recently published meta-analysis and meta-regression analysis demonstrating the main parameters of euDKA in patients with T1DM treated with SGLT-2 inhibitors: Musso G, Sircana A, Saba F, Cassader M, Gambino R. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression. *PLoS Med.* 2020;17(12):e1003461. Published 2020 Dec 29. doi:10.1371/journal.pmed.1003461.

Response: We thank the reviewer for reminding us to include this recent metanalysis. This article is added to the manuscript. (Page 7, Para 1, Line 6)

We have also added recent NICE guidance on SGLT-2 inhibitors for the treatment of Type I DM. (Page 7, Para 1, Line 11)